脑心通治疗2型糖尿病合并冠心病、慢性心功能不全临床对比观察

Clinical Comparative Observation of Naoxintong Capsule in the Treatment of Type 2 Diabetes Mellitus Complicated with Coronary Heart Disease and Chronic Cardiac Insufficiency

目的：探讨脑心通胶囊治疗2型糖尿病合并冠心病的疗效与安全性。方法：对56例确认为2型糖尿病合并冠心病、慢性心功能不全（心功能≥Ⅱ级）的患者随机分成两组。其中28例按指南常规治疗（包括血糖控制、抗血小板治疗、β-受体阻滞剂、降脂治疗、ACEI、长效CCB、硝酸酯类、心衰加用强心剂等）,作为对照组;另外28例在对照组的基础上加用脑心通胶囊每次4粒,每日3次,作为治疗组。疗程3个月,比较两组疗效、心电图改变、N型脑利钠肽前体（BNP）、C-反应蛋白（CRP）、左室射血分数（LVEF）、心功能改善情况、不良反应及用药的依从性。结果：脑心通胶囊组治疗2型糖尿病合并冠心病、慢性心功能不全的疗效、症状改善情况、心电图改变、N型脑利钠肽前体（BNP）、C-反应蛋白（CRP）、左室射血分数（LVEF）均优于对照组（P≤0.05）,两组观察期间均未发现明显的不良反应,患者依从性无明显差别。结论：脑心通胶囊治疗2型糖尿病合并冠心病、慢性心功能不全安全、有效,不良反应少,患者依从性好,临床应用前景好。

Objective：To explore the efficacy and safety of Naoxintong Capsule in the treatment of type 2 diabetes mellitus complicated with coronary heart disease.Methods：56 cases of patients with type 2 diabetes mellitus with coronary heart disease in Jingdezhen first people＇s Hospital in Jiangxi from Jaunary 2015 to March 2016 were selected as the objects,and were divided into control group and treatment group randomly,twenty-eight cases in each group.The control group was treated according to the guidelines（including：blood glucose control,antiplatelet therapy,beta blockers,lipid-lowering therapy,ACEI,long-acting CCB,nitrates,heart failure with tonic）,and the treamtent group were added NaoxintongCapsule on the basis of the control group,treatment for three months in the two groups.Clinical the therapeutic of the two groups and changes of electrocardiogram（ECG）before and after treatment were compared,and N-type brain natriuretic peptide precursor（BNP） and C-reactive protein（CRP）were tasted before and after treatment in the two groups,and changes of left ventricular ejection fraction and cardiac function improvement were evaluated,and adverse reactions,and drug compliance were observed in the two groups in treatment.Results：In the treatment of type 2 diabetes mellitus complicated with coronary heart disease and chronic heart failure,improvement of symptoms,changes of electrocardiogram（ECG）,N-type natriuretic peptide precursor,C-reactive proteinand changes of left ventricular ejection fraction,the treatment group were better than those in the control group.There was no signficant difference in incidence of adverse reactions between the two groups.Conclusion：Naoxintong Capsule in the treatment of type 2 diabetes complicated with coronary heart disease and chronic cardiac insufficiency is safe,effective,less adverse reactions,good patient compliance,clinical application prospects are good.